Fidelity Disruptors ETF (FDIF) News

Dr. Jamil should know that once it is established that the primary endpoint has not been reached, it is widely recognised that it is not valid statistically to declare secondary endpoints and other sub-analyses as having reached statistical significance.

It’s a (not very) sophisticat

The Overhead Trendline, The 2.50 Level, The Overall Crypto Sector......

Boy.......what ppl steer clear of considering here is a real mindblower.......


https://investorshub.advfn.com/uimage/uploads/2025/1/13/rmobiXRP_!_12_45d_6pm_GLITCH_OHTL_250_SUMMARY.jpg

You contradict yourself......" style="caret-color: rgb(33, 37, 41); color: rgba(33, 37, 41, 1); font-family: Nunito, serif; background-color: rgba(255, 255, 255, 1); font-size: 1em"IF YOU owned P's, K's, or uq's ? ... the DTC Knows It' ... and, the DTC Knows EXACTLY How Many P's, K's, or uq's ... YO

Hello, I'm a newbie at AIM. Wondering if someone could recommend or provide a good spreadsheet?
roncderu@gmail.com.

If the predictions are correct it is going to be an interesting week.

PORTHOS still on schedule. Seems like spring/summer commissioning
https://www.linkedin.com/posts/porthos-co2_porthos-porthosco-co2-activity-7282763014376677376-qnb-?utm_source=share&utm_medium=member_android

https://www.linkedin.com/posts/activity-7275803191202447360-EX6x?utm

Hi all, thanks for happy new year wishes and I wish the same for all here too!

>>> Abbott Laboratories (NYSE: ABT) is a well-diversified healthcare company, with four distinct units: Medical devices, diagnostics, nutrition, and established pharmaceuticals. This is great because it means if one of these businesses faces tough times, another could compensate and maintain overall

>>> Abbott Laboratories (NYSE: ABT) is a well-diversified healthcare company, with four distinct units: Medical devices, diagnostics, nutrition, and established pharmaceuticals. This is great because it means if one of these businesses faces tough times, another could compensate and maintain overall

Steady I think the rubber hits the road when we see the MHRA label assignment on L. Based on safety, phase 3 and RWE we just might see a broad scope label which I’ll call a home run.

If what you suggest is a possibility, I would view the early December "Investor's Day" in hindsight as more of a dog and pony show for potential buyers. At this point, investors have been beaten to the point that most of us would accept if the company was sold for $6 or $7 a share. What would that b

In October of 2023 The best setup in the OTC challenge was posted and ATMH still holds the #1 spot! Not one ticker has been found with a better setup! 🏆️

If anyone wants to take the challenge and prove me wrong here is the link https://investorshub.advfn.com/b

We will persevere!

>>> Intuitive Surgical (NASDAQ: ISRG) is the global leader in robotic surgery. With a compound annual growth rate of about 15%, this market is expected to reach more than $25 billion by 2030, according to Meticulous Research. Intuitive's flagship product is the da Vinci, a system used in a wide vari

We know who you are!

>>> Intuitive Surgical (NASDAQ: ISRG) is the global leader in robotic surgery. With a compound annual growth rate of about 15%, this market is expected to reach more than $25 billion by 2030, according to Meticulous Research. Intuitive's flagship product is the da Vinci, a system used in a wide vari

Not "walking dead", just dead. I just wish they'd declare bankruptcy instead of pretending like it's going to trade again.

Clearly, Port turned out to be the fool. Actually, he made fools of all you guys who bought into his scam.

In the comment section of this article,
https://seekingalpha.com/article/4748984-playing-the-odds-of-anavex-alzheimers-drug-approval#scroll_comments

Someone named Stephen Ayers in his Saturday, 12:42PM comment, says

I asked ChatGPT why the following statement, w

It's not going to be audited. They lied again. They do that once a year. Been that way for the last 4 years.

has announced that it will be paying its dividend of $0.43 on the 7th of March, an increased payment from last year's comparable dividend. This makes the dividend yield 6.5%, which is above the industry average

$PFE

You might be correct about the size of the GBM market in the UK. However you are missing the point.

Approval in the UK validates the MOA and the potential of treating other solid cancers. That will have much more impact than the limited size of the UK market.

Approval

While I'd love you to be right, that would represent over a $14 billion market cap, I believe that's high until the EDEN is available for production of the vaccine. I just don't believe that enough vaccine can be produced in Sawston to justify that market cap until they can make more, which require

Putz: We are not at 2 years. Who's we? LoL SMH

Keep an eye on the door. Big revelation! It's coming. UK